Talecris Biotherapeutics

  Home About Talecris Therapeutic Areas Research & Development Donor to Patient Business Development Investor Relations Media Center  
Media Center Overview
Press Releases
News Features
The History of Talecris
Talecris Leadership
Talecris Media Contact Information

The History of Talecris


2008

  Prolastin DirectSM delivery program launched in Canada.

2008

  Precision Pharma Services merges into Talecris Biotherapeutics.

2008

  Talecris celebrates 20th anniversary of launch of Prolastin® Alpha1-Proteinase Inhibitor (Human).

2007

  Talecris honored as an Industry Week 2007 Best Plants Award Finalist.

2007

  Talecris initiates clinical development program evaluating plasmin for dissolving blood clots and restoring blood flow in legs.

2006

  Talecris announces the formation of Talecris Plasma Resources and the purchase of its own plasma collection centers.
2006   Launch of Talecris Talents, an annual million-dollar grant program to fund basic and clinical research involving use of intravenous immunoglobulin.
2006   Talecris expands into Canada (April 1) and Europe (December 1).
2005   Talecris receives QSEAL certification from the Plasma Protein Therapeutics Association (PPTA).
2005   Talecris Biotherapeutics established in United States, acquiring the contributed assets of the worldwide plasma business of Bayer BP and the additional fractionation capacity and contract manufacturing services of Precision Pharma Services.
 
2004   Bayer BP is first plasma fractionator to receive FDA approval for in-house nucleic acid testing (NAT) of human immunodeficiency virus (HIV).
 
2004   Launch of Gamunex® Immune Globulin Intravenous (Human), 10% Caprylate / Chromatography Purified.
2003   Bayer BP uses innovative viral inactivation technology (caprylate) in the production of IGIV.
2002   Bayer BP is first company in biological products industry to launch Tamper-Evident-Packaging (TEP).
2001   Bayer BP develops Western Blot Assay methodology for testing plasma purification during the manufacture of therapeutic proteins, the first of its kind in the biological products industry.
 
2001   Melville, N.Y. facility purchased by Ampersand Ventures and renamed Precision Pharma Services.
1999   Innovative drug distribution program created (now called Prolastin DirectSM) for alpha-1 patient; includes services of AlphaNet Coordinators.
 
1999   Clayton, N.C. facility fractionation capacity reaches 1.9 million liters per year.
1995   Miles Inc. renamed Bayer Corporation.
1992   Bayer AG merges its U.S. subsidiaries to form Miles, Inc.
1988   Launch of Prolastin®, Alpha1- Proteinase Inhibitor (Human), first proteinase inhibitor product.
1981   Miles Laboratories, Inc. is granted approval for the first liquid intravenous immune globulin (IGIV), Gamimune®, Immune Globulin Intravenous (Human).
 
1980   Precision Pharma Services predecessor New York Blood Center (Melville Biologics) facility in Melville, N.Y. is licensed by the FDA.
1978   Bayer acquires Miles Laboratories, Inc. 
1974   Cutter acquired by Miles Laboratories, Inc. 
1974   Cutter completes Clayton, N.C. facility and begins producing product with a staff of 100 and a capacity of 375,000 liters per year.
1972   Cutter Laboratories breaks ground in Clayton, N.C.
 
1942 Cutter Laboratories pioneers plasma fractionation and develops first blood product, albumin.


 

 

Print This Page
E-mail This Page
Talecris Biotherapeutics
Contact Talecris    Glossary    Site Map
General Conditions of Use    Privacy Statement    California Compliance
© 2009 Talecris Biotherapeutics